# Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

> **NCT06558084** · — · COMPLETED · sponsor: **Ain Shams University** · enrollment: 64 (actual)

## Conditions studied

- Toxicity, Drug
- Progression, Disease

## Interventions

- **DRUG:** CDK4/6 Inhibitor

## Key facts

- **NCT ID:** NCT06558084
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-06
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-08-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558084, "Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06558084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*